



17 November 2011

Sphere Medical Holding plc

Sphere Medical announces new non-executive directors

Cambridge, UK, 17 November 2011: Sphere Medical Holding plc (AIM:SPHR.L) ("Sphere Medical" or the "Company") is pleased to announce that Stephen Mahle and John Gregory have joined the Company's Board as Non-Executive Directors. Mr Gregory has been appointed the senior Independent Director and will Chair the Audit Committee.

Mr Mahle is the former Executive Vice President of Medtronic Inc, one of the world's largest medical device companies, retiring in September 2009 after 37 years. Mr Mahle joined Medtronic in 1972 and held numerous senior leadership positions with the company. For 17 years Mr Mahle led Medtronic's largest division as President of the Pacing Business and subsequently as President of Cardiac Rhythm Disease Management.

Mr Gregory is a chartered accountant who for the last 17 years has concentrated on non-executive roles with young, fast-growing companies. Mr Gregory was chairman of IS Pharma plc through the merger with Sinclair Pharma plc, subsequently becoming non-executive chairman of the merged group until he relinquished this role following the successful integration of the companies in September 2011. Currently he is non-executive chairman of Foresight VCT plc, and a non-executive director of a number of private companies. In March 2011, Mr Gregory was named 'AIM Non-Executive Director of the Year' in the annual Peel Hunt and Sunday Times sponsored Non-Executive director Awards.

Previous non-executive directors, Mr Bob Pettigrew and Mr William Mason, have now stepped down from the board.

The information required in accordance with Schedule 2 paragraph (g) of the AIM Rules is contained in the Company's AIM Admission Document dated 11 November 2011, a copy of which can be obtained from the Company's web site.

Commenting on the new board members, Chief Executive Officer, Dr Stuart Hendry, said:

"Mr Gregory and Mr Mahle bring a wealth of experience to Sphere Medical's Board at a time when the Company is transitioning to a publicly listed company on AIM and approaching the commercialisation phase for its lead products. I would like to take this opportunity to thank Mr Pettigrew and Mr Mason for their service and contribution to the Company over the years."

Commenting on his appointment, Stephen Mahle said:

"I am delighted to be joining the board of Sphere Medical as they begin to launch a line of critical care patient monitoring products that has the potential to improve patient outcomes, simplify the care of critically ill patients and reduce health care costs. It is the combination of these three elements that lead me to believe that Sphere can provide exactly the kind of technology solutions to meet the challenges of 21st century medicine."

Commenting on his appointment, John Gregory said

"I am fortunate to have been invited to join the board of Sphere Medical. It is a company on the threshold of commercialising the application of its unique platform technology. Its initial products are for use in hospital settings and have the potential to enhance patient care and consequently reduce costs of patient treatment. I look forward to working with Sphere's outstanding executive team."



For further information, please contact:

Sphere Medical Holding plc

Dr Stuart Hendry, Chief Executive Officer
Matthew Hall, Chief Financial Officer

Tel: +44 (0)1223 875222

Peel Hunt LLP

James Steel
Matthew Armit / Dr Vijay Barathan
Harry Florry

Tel: +44 (0) 20 7418 8900

Buchanan Communications

Tim Anderson
Lisa Baderoon

Tel: +44 (0) 20 7466 5000

www.spheremedical.com

Notes for Editors

Sphere Medical is a UK based medical device company completing the development of a range of monitoring and diagnostic products designed to provide significant improvements in patient management in a number of hospital specialities. Sphere Medical's products are expected to allow near real time measurement of blood gases, various electrolytes and drug levels with laboratory accuracy, at the patient's bedside. This information can be used in a wide range of medical applications and is intended to enable faster clinical decision making and consequently to improve the management of patients.

Sphere Medical's two most advanced products, based on its proprietary microanalyser platform technology, are a disposable patient-attached arterial blood analyser for use in the Intensive Care Unit and Operating Room ('**Proxima**') and a device for continuous blood monitoring in the bypass circuit in patients undergoing cardiopulmonary bypass surgery ("**CPB device**"). Sphere Medical has also developed and is selling a device ('**Pelorus 1000**') that can measure blood levels of the intravenously administered anaesthetic drug, propofol. In each case, these products will ultimately target patients requiring close monitoring and frequent levels of blood testing.

Sphere Medical employs 43 staff in the areas of research and development, product development, sales and marketing and management and operations at its premises at Harston, Cambridge, UK.